Transmission fitness of drug-resistant human immunodeficiency virus and the prevalence of resistance in the antiretroviral-treated population

被引：1
|
作者：
Brown, AJL
Frost, SDW
Mathews, WC
Dawson, K
Hellmann, NS
Daar, ES
Richman, DD
Little, SJ
机构：
[1] Univ Edinburgh, Inst Cell Anim & Populat Biol, Ashworth Labs, Edinburgh EH9 3JT, Midlothian, Scotland
[2] Univ Calif San Diego, Dept Pathol, San Diego, CA 92103 USA
[3] Univ Calif San Diego, Dept Med, San Diego, CA 92103 USA
[4] ViroLogic, San Francisco, CA USA
[5] Harbor Univ Calif Los Angeles Med Ctr, Torrance, CA USA
[6] Vet Affairs San Diego Healthcare Syst, La Jolla, CA USA
来源：
JOURNAL OF INFECTIOUS DISEASES | 2003年 / 187卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Although the prevalence of drug-resistant strains in primary human immunodeficiency virus (HIV) infection in North America has recently increased, their transmission fitness remains unknown. The present study estimated the frequency of transmission of drug-resistant HIV from patients receiving antiretroviral therapy using retrospective surveys of clinic data. It revealed that resistant virus was transmitted only similar to20% as frequently as expected from these patients. Individuals with primary resistance may become a significant source of resistant strains.
引用
收藏
页码：683 / 686
页数：4
相关论文
共 50 条
  • [1] Changing transmission fitness of drug-resistant human immunodeficiency virus against a background of evolving antiretroviral therapy - Reply
    Brown, AJL
    Frost, SDW
    Mathews, WC
    Dawson, K
    Hellmann, NS
    Daar, ES
    Richman, DD
    Little, SJ
    JOURNAL OF INFECTIOUS DISEASES, 2003, 188 (08): : 1258 - 1259
  • [2] Randomized Trial of Ruxolitinib in Antiretroviral-Treated Adults With Human Immunodeficiency Virus
    Marconi, Vincent C.
    Moser, Carlee
    Gavegnano, Christina
    Deeks, Steven G.
    Lederman, Michael M.
    Overton, Edgar T.
    Tsibris, Athe
    Hunt, Peter W.
    Kantor, Amy
    Sekaly, Rafick-Pierre
    Tressler, Randall
    Flexner, Charles
    Hurwitz, Selwyn J.
    Moisi, Daniela
    Clagett, Brian
    Hardin, William R.
    Del Rio, Carlos
    Schinazi, Raymond F.
    Lennox, Jeffrey J.
    CLINICAL INFECTIOUS DISEASES, 2022, 74 (01) : 95 - 104
  • [3] Strong cell-mediated immune responses are associated with the maintenance of low-level viremia in antiretroviral-treated individuals with drug-resistant human immunodeficiency virus type 1
    Deeks, SG
    Martin, JN
    Sinclair, E
    Harris, J
    Neilands, TB
    Maecker, HT
    Hagos, E
    Wrin, T
    Petropoulos, CJ
    Bredt, B
    Mccune, JM
    JOURNAL OF INFECTIOUS DISEASES, 2004, 189 (02): : 312 - 321
  • [4] Spread of a low-fitness drug-resistant Mycobacterium tuberculosis strain in a setting of high human immunodeficiency virus prevalence
    Strauss, O. J.
    Warren, R. M.
    Jordaan, A.
    Streicher, E. M.
    Hanekom, M.
    Falmer, A. A.
    Albert, H.
    Trollip, A.
    Hoosain, E.
    van Helden, P. D.
    Victor, T. C.
    JOURNAL OF CLINICAL MICROBIOLOGY, 2008, 46 (04) : 1514 - 1516
  • [5] Progressive reversion of human immunodeficiency virus type 1 resistance mutations in vivo after transmission of a multiply drug-resistant virus
    Gandhi, RT
    Wurcel, A
    Rosenberg, ES
    Johnston, MN
    Hellmann, N
    Bates, M
    Hirsch, MS
    Walker, BD
    CLINICAL INFECTIOUS DISEASES, 2003, 37 (12) : 1693 - 1698
  • [6] Induction of T-cell immunity to antiretroviral drug-resistant human immunodeficiency virus type 1
    Stratov, I
    Dale, CJ
    Chea, S
    McCluskey, J
    Kent, SJ
    JOURNAL OF VIROLOGY, 2005, 79 (12) : 7728 - 7737
  • [7] The impact of human immunodeficiency virus infection on drug-resistant tuberculosis
    Gordin, FM
    Nelson, ET
    Matts, JP
    Cohn, DL
    Ernst, J
    Benator, D
    Besch, CL
    Crane, LR
    Sampson, JH
    Bragg, PS
    ElSadr, W
    Koyande, D
    Pollard, C
    Telzak, E
    Standridge, B
    Zahnow, K
    Waldmann, C
    Walker, J
    Pablovich, S
    Kissinger, P
    Deisinger, G
    Fleming, D
    Neer, C
    Merkering, TM
    Miller, GB
    Hales, D
    Roybal, A
    Saravolatz, L
    Faber, L
    Kumi, J
    Sivapalan, V
    Guity, C
    Torres, RA
    Dowling, C
    Zbikowski, V
    Krupa, R
    Sullivan, R
    LuskinHawk, R
    Taylor, VM
    AlHaddadin, D
    Moaven, N
    Brown, LS
    John, SL
    Ellison, J
    Muth, K
    Miatico, MG
    Deyton, B
    Groom, C
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1996, 154 (05) : 1478 - 1483
  • [8] Snake venom preparation for drug-resistant human immunodeficiency virus
    Alrajhi, Abdulrahman A.
    Almohaizeie, Abdullah
    ANNALS OF SAUDI MEDICINE, 2008, 28 (04) : 292 - 293
  • [9] Human immunodeficiency virus coinfection with drug-resistant Mycobacterium tuberculosis
    Iringó Erzsébet Zaharia-Kézdi
    Carmen Chiriac
    Andrea Incze
    Nina Șincu
    Lilla Lorinczi
    Mihaela Patraulea
    BMC Infectious Diseases, 13 (Suppl 1)
  • [10] Antiretroviral Drug Resistance in Human Immunodeficiency Virus Type 2
    Ntemgwa, Michel L.
    Toni, Thomas d'Aquin
    Brenner, Bluma G.
    Camacho, Ricardo J.
    Wainberg, Mark A.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2009, 53 (09) : 3611 - 3619
12345